Bayer plans to invest $2.2 billion in a pharmaceutical manufacturing campus in New Albany, Ohio, creating about 600 permanent jobs and roughly 1,500 temporary construction positions. The first drug substance manufacturing module is scheduled to become operational in 2031, followed by a finished-drug product facility in 2034. Bayer has increased the U.S. share of its pharmaceuticals revenue to 35% from 20% in 2018 and aims to double U.S. sales by the end of the decade. The expansion is expected to support products including Kerendia for chronic kidney disease, Nubeqa for prostate cancer and the stroke-prevention candidate asundexian. Bayer said the investment will strengthen its U.S. manufacturing presence alongside its established operations in Europe and Asia. The project builds on more than $7 billion in U.S. pharmaceutical research, development and manufacturing spending during the past five years. Ohio officials and JobsOhio said the site will add to New Albany’s life sciences cluster and draw on the Ohio Life Science Training Center, which is scheduled to open in summer 2027. The investment comes as President Donald Trump pressures drugmakers to lower U.S. prescription prices while urging other developed countries to pay more.